UPDATE: Credit Suisse Downgrades PDL Biopharma to Underperform on Valuation

Credit Suisse downgraded PDL BioPharma, Inc.

from Neutral to Underperform and lowered the price target from $6.50 to $6.00. Credit Suisse commented, "We are downgrading PDLI to Underperform to balance our portfolio of ratings and reflect our view that the stock price is above our fair value calculation. Unlike other names we cover, PDLI lacks significant optionality as new products deliver a finite and relatively short revenue stream. The high regular dividend, potential for special dividends, and a lack of visible downside triggers make PDLI an "expensive" short, which is not our recommendation." PDL Biopharma closed at $7.42 on Monday.